The first academic center activated to enroll, led by an instrumental investigator who participated in Femasys’ earlier FemBloc studies -FemBloc…
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral…
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult…
SIKLOS® (hydroxyurea) is now covered by State Medicaid programs in 19 states Medunik USA (member of Duchesnay Pharmaceutical Group) is…
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and…
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs…
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…
Grant from Bill & Melinda Gates Foundation will facilitate development of AI-assisted applications and tools to enable healthcare professionals with…
Additional Providers Increase Biospecimen Access for Researchers Focused on Cervical, Uterine and Breast Cancers, as well as Reproductive Health, Cardiovascular…